Towards the development of specific antidotes: Idarucizumab for reversal of dabigatran effects
- PMID: 25926042
- DOI: 10.1160/TH15-04-0324
Towards the development of specific antidotes: Idarucizumab for reversal of dabigatran effects
Comment on
-
A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.Thromb Haemost. 2015 May;113(5):943-51. doi: 10.1160/TH14-12-1080. Epub 2015 Mar 19. Thromb Haemost. 2015. PMID: 25789661 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical